Evaluation of [13N]- Ammonia- and [18F]-FDG-PET/cMRI for Cardiac Sarcoidosis

Go Back to All Clinical Trials

Evaluation of [13N]- Ammonia- and [18F]-FDG-PET/cMRI for Cardiac Sarcoidosis

Brief description of study

The purpose of this study is to evaluate the accuracy and clinical significance or benefit of using a combined [13N]- Ammonia- and [18F]-FDG-PET/cMRI for evaluation of cardiac sarcoidosis and to assess the biomarkers associated with the disease. Positron Emission Tomography, commonly referred to as PET involves the use of injected compounds known as radiotracers (like [13N]-Ammonia and [18F] FDG) to make images that give us information about conditions in your body. In contrast, Magnetic Resonance Imaging or MRI uses a magnet instead of radiation to visualize the inside of your body. Contrast (dye) is commonly injected to enhance the clarity of the images.

Clinical Study Identifier: s18-00729

Principal Investigator: Kent P Friedman.

Other Investigators: Jeffrey B. Alpert, Lawrence Phillips, Robert M Donnino, Leon Axel.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies